KPTI
BEARISH
$8.0
Live
Karyopharm Therapeutics Inc. · NASDAQ
Target $11.0
(+37.5%)
$3.65
52W Range
$10.99
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$180.35M
P/E
N/A
ROE
N/A
Profit margin
-134.2%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
90%
KPTI exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.50, indicating negative shareholder equity. While the stock has seen a speculative 1-year price surge of 100.5%, the underlying fundamentals are catastrophic with a profit margin of -134.21% and a consistent track record of missing earnings estimates (0/4 in the last year). Despite bullish analyst targets, the combination of insider selling and extreme operational inefficiency suggests a high risk of further capital erosion.
Key Strengths
Positive year-over-year revenue growth of 11.60%
Recent 1-year price recovery (+100.5%)
Improving EPS growth trend (+38.1% YoY), though still deeply negative
Current ratio of 1.12 provides minimal short-term liquidity
Positive analyst sentiment with a target price of $11.00
Key Risks
Negative Book Value (P/B -0.50) indicating insolvency risk
Extreme operational losses (Profit Margin -134.21%)
Critical Piotroski F-Score (1/9) signaling fundamental weakness
Consistent failure to meet earnings expectations (0/4 beats in last 4 quarters)
Abnormally low gross margin (9.93%) for a biotechnology firm
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
14
Weak
10
40
15
5
0
AI Verdict
High Risk / Speculative
Key drivers: Negative equity, Piotroski F-Score 1/9, Severe profit margins, Insider selling
Confidence
95%
Value
10/100
Trades at a negative book value, rendering traditional value metrics useless.
Positives
- Low Price/Sales ratio (1.23)
Watchpoints
- Negative P/B ratio
- No Graham Number possible due to negative earnings/book value
Future
40/100
Growth is present but insufficient to offset massive burn rates.
Positives
- Modest revenue growth
- EPS is becoming less negative
Watchpoints
- 0% beat rate on recent earnings
- Negative forward P/E
Past
15/100
Historical performance shows a near-total loss of capital over 5 years.
Positives
- Strong 1-year recovery
Watchpoints
- 5-year return of -94.7%
- Long-term value destruction
Health
5/100
Fundamental health is in a state of collapse.
Positives
- Current ratio slightly above 1.0
Watchpoints
- Piotroski F-Score 1/9
- Negative equity
- ROA of -41.56%
Dividend
0/100
Non-dividend paying growth/distress stock.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No capacity for dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$8.0
Analyst Target
$11.0
Upside/Downside
+37.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for KPTI and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
KPTI
Karyopharm Therapeutics Inc.
Primary
|
-94.7% | -87.2% | +100.5% | +45.5% | -8.6% | +35.8% |
|
LFCR
Lifecore Biomedical, Inc.
Peer
|
-52.8% | +24.4% | -17.0% | -26.9% | -30.2% | +23.7% |
|
KRRO
Korro Bio, Inc.
Peer
|
-97.3% | -46.2% | -2.2% | -70.5% | +7.8% | -9.4% |
|
INGN
Inogen, Inc.
Peer
|
-88.6% | -52.4% | -10.6% | -22.4% | +1.6% | +1.9% |
|
ARCT
Arcturus Therapeutics Holdings Inc.
Peer
|
-87.2% | -57.7% | -51.9% | -61.4% | -9.7% | -6.0% |
KPT
Karyopharm Therapeutics Inc.
Primary
5Y
-94.7%
3Y
-87.2%
1Y
+100.5%
6M
+45.5%
1M
-8.6%
1W
+35.8%
LFC
Lifecore Biomedical, Inc.
Peer
5Y
-52.8%
3Y
+24.4%
1Y
-17.0%
6M
-26.9%
1M
-30.2%
1W
+23.7%
KRR
Korro Bio, Inc.
Peer
5Y
-97.3%
3Y
-46.2%
1Y
-2.2%
6M
-70.5%
1M
+7.8%
1W
-9.4%
ING
Inogen, Inc.
Peer
5Y
-88.6%
3Y
-52.4%
1Y
-10.6%
6M
-22.4%
1M
+1.6%
1W
+1.9%
ARC
Arcturus Therapeutics Holdings Inc.
Peer
5Y
-87.2%
3Y
-57.7%
1Y
-51.9%
6M
-61.4%
1M
-9.7%
1W
-6.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.83
PEG Ratio
N/A
P/B Ratio
-0.5
P/S Ratio
1.23
EV/Revenue
2.66
EV/EBITDA
-4.3
Market Cap
$180.35M
Profitability
Profit margins and return metrics
Profit Margin
-134.21%
Operating Margin
-52.36%
Gross Margin
9.93%
ROE
N/A
ROA
-41.56%
Growth
Revenue and earnings growth rates
Revenue Growth
+11.6%
Earnings Growth
N/A
Q/Q Revenue Growth
+11.58%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
1.12
Good
Quick Ratio
0.98
Poor
Cash/Share
$3.48
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
95.6%
Op. Margin
-52.4%
Net Margin
-299.9%
Total Assets
$0.1B
Liabilities
$0.4B
Equity
$-0.3B
Debt/Equity
-1.37x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-11
$N/A
2026-02-12
$-2.23
-11.3% surprise
2025-11-03
$-3.82
-8.4% surprise
2025-08-11
$-4.07
-4.0% surprise
Healthcare Sector Comparison
Comparing KPTI against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
Profit Margin
-134.21%
This Stock
vs
-9.43%
Sector Avg
+1322.7%
(Superior)
Revenue Growth
11.6%
This Stock
vs
80.78%
Sector Avg
-85.6%
(Slower)
Current Ratio
1.12
This Stock
vs
3.72
Sector Avg
-69.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
KPTI
Karyopharm Therapeutics Inc.
|
BEARISH | $180.35M | - | -% | -134.2% | $8.0 | |
|
LFCR
Lifecore Biomedical, Inc.
|
BEARISH | $178.02M | - | -% | -23.8% | $4.75 | Compare |
|
KRRO
Korro Bio, Inc.
|
BEARISH | $182.88M | - | -110.7% | -% | $12.68 | Compare |
|
INGN
Inogen, Inc.
|
BEARISH | $172.38M | - | -12.4% | -6.5% | $6.33 | Compare |
|
ARCT
Arcturus Therapeutics Holdings Inc.
|
BEARISH | $189.87M | - | -28.9% | -80.2% | $6.68 | Compare |
KPTI
Karyopharm...
BEARISH
Mkt Cap
$180M
P/E
-
ROE
-%
Price
$8.0
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | PAULSON RICHARD A. | Chief Executive Officer | Sale | 12,361 | $116,311 |
| 2026-03-02 | RANGWALA RESHMA | Officer | Sale | 5,066 | $47,669 |
| 2026-03-02 | MANO MICHAEL | Officer | Sale | 3,526 | $33,178 |
| 2026-03-02 | CHENG SOHANYA ROSHAN | Officer | Sale | 4,604 | $43,321 |
| 2026-03-02 | POULTON STUART | Officer | Sale | 5,101 | $47,998 |
| 2026-03-02 | ABATE KRISTIN | Officer | Sale | 559 | $5,260 |
| 2026-02-17 | POULTON STUART | Officer | Sale | 378 | $3,262 |
| 2026-02-05 | PAULSON RICHARD A. | Chief Executive Officer | Stock Award | 81,060 | - |
| 2026-02-03 | MACOMBER LORI A | Chief Financial Officer | Sale | 1,626 | $10,244 |
| 2026-01-30 | RANGWALA RESHMA | Officer | Stock Award | 32,415 | - |
| 2026-01-30 | MANO MICHAEL | Officer | Stock Award | 32,415 | - |
| 2026-01-30 | CHENG SOHANYA ROSHAN | Officer | Stock Award | 32,415 | - |
| 2026-01-30 | MACOMBER LORI A | Chief Financial Officer | Stock Award | 32,415 | - |
| 2026-01-30 | POULTON STUART | Officer | Stock Award | 32,415 | - |
| 2026-01-28 | ABATE KRISTIN | Officer | Sale | 50 | $352 |
PAULSON RICHARD A.
Chief Executive Officer
2026-03-02
12,361 shares
·
$116,311
RANGWALA RESHMA
Officer
2026-03-02
5,066 shares
·
$47,669
MANO MICHAEL
Officer
2026-03-02
3,526 shares
·
$33,178
CHENG SOHANYA ROSHAN
Officer
2026-03-02
4,604 shares
·
$43,321
POULTON STUART
Officer
2026-03-02
5,101 shares
·
$47,998
ABATE KRISTIN
Officer
2026-03-02
559 shares
·
$5,260
POULTON STUART
Officer
2026-02-17
378 shares
·
$3,262
PAULSON RICHARD A.
Chief Executive Officer
2026-02-05
81,060 shares
MACOMBER LORI A
Chief Financial Officer
2026-02-03
1,626 shares
·
$10,244
RANGWALA RESHMA
Officer
2026-01-30
32,415 shares
MANO MICHAEL
Officer
2026-01-30
32,415 shares
CHENG SOHANYA ROSHAN
Officer
2026-01-30
32,415 shares
MACOMBER LORI A
Chief Financial Officer
2026-01-30
32,415 shares
POULTON STUART
Officer
2026-01-30
32,415 shares
ABATE KRISTIN
Officer
2026-01-28
50 shares
·
$352
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
6 analysts
Piper Sandler
2026-03-30
Overweight
Overweight
Baird
2026-03-25
Outperform
Outperform
HC Wainwright & Co.
2026-03-25
Buy
Buy
Rodman & Renshaw
2026-03-10
Buy
HC Wainwright & Co.
2026-02-18
Buy
Buy
Cantor Fitzgerald
2026-02-05
Overweight
RBC Capital
2025-11-04
Outperform
Outperform
Past News Coverage
Recent headlines mentioning KPTI from our newsroom.
Newest → oldest
No matching news yet.